A.A. van de Loosdrecht passed Medical School (cum laude) in 1989 at the VU University Medical Center in Amsterdam, The Netherlands. He received his PhD graduation (cum laude) in 1993 at the same University and graduated in Immunology in 1995. From 1993-1998 he followed clinical training in Internal Medicine followed by hematology at the Groningen University Medical Center, Netherlands. From 2000, he is a staff member and since 2012 a full professor of hematology at the department of Hematology, Amsterdam UMC. He is principal investigator of the preclinical and translational immunotherapy programs in AML and MDS. The major research lines focus on the immunopathogenesis of MDS/AML and on the development of leukemic dendritic cell vaccines for active specific immunization in patients with minimal residual disease (MRD). He is coordinator of HORIZON2020, AML-VACCiN program dealing with Dendritic Cell vaccination in AML. In MDS research focuses on the implementation of flow cytometry in MDS diagnosis and prognosis. He initiated a platform within the ELN on the implementation of flowcytometry in MDS. He is chair of the Database Sharing Committee of the International Working Group for Prognosis of MDS (IWG-PM) and board member of the Dutch HOVON working group on AML and MDS.

Norbert Vey MD is Professor of Hematology at Aix-Marseille University, Marseilles, France. He is Director of the Hematology Department and General Director of Institut Paoli-Calmettes Cancer Center in Marseille, France. Pr Vey is Vice-President of the Groupe Francophone des Myélodysplasies (GFM), member of the executive committee of the French Innovative Leukemia Organization (FILO) group. He has authored more than 350 indexed publications within the fields of leukemia, MDS and bone marrow transplantation. Pr Vey’s main research interests include developmental therapeutics for leukemias and myelodysplastic syndromes.